# Gregory A. Abel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gregory-a-abel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,767 |
| Field | Acute Myeloid Leukemia Research |
| h-index | 45 |
| i10-index | 127 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5091710463 |
| ORCID iD | 0000-0003-1100-2813 |
| Works | 351 |

## Researcher papers

- [An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era](https://scholariq.org/papers/an-enhanced-international-prognostic-index-nccn-ipi-for-patients-with-diffuse/)
- [Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia](https://scholariq.org/papers/cost-sharing-and-adherence-to-tyrosine-kinase-inhibitors-for-patients-with/)
- [Race-Ethnic Disparities in the Impact of Stroke Risk Factors](https://scholariq.org/papers/race-ethnic-disparities-in-the-impact-of-stroke-risk-factors/)
- [Frailty and the management of hematologic malignancies](https://scholariq.org/papers/frailty-and-the-management-of-hematologic-malignancies/)
- [Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies](https://scholariq.org/papers/gait-speed-grip-strength-and-clinical-outcomes-in-older-patients-with/)
- [American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults](https://scholariq.org/papers/american-society-of-hematology-2020-guidelines-for-treating-newly-diagnosed/)
- [Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review](https://scholariq.org/papers/defining-undertreatment-and-overtreatment-in-older-adults-with-cancer-a-scoping/)
- [End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists](https://scholariq.org/papers/end-of-life-care-for-blood-cancers-a-series-of-focus-groups-with-hematologic/)
- [Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia](https://scholariq.org/papers/health-care-utilization-and-end-of-life-care-for-older-patients-with-acute/)
- [Barriers to Quality End-of-Life Care for Patients With Blood Cancers](https://scholariq.org/papers/barriers-to-quality-end-of-life-care-for-patients-with-blood-cancers/)
- [Comparative rates of adverse events with different formulations of intravenous iron](https://scholariq.org/papers/comparative-rates-of-adverse-events-with-different-formulations-of-intravenous/)

## Researcher topics

- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Palliative Care and End-of-Life Issues](https://scholariq.org/topics/palliative-care-and-end-of-life-issues/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.